Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.

US pharma major Bristol Myers Squibb’s shares remained steady, despite the company reporting disappointing results from its ...

Bristol Myers Squibb acknowledged that a phase III trial of luspatercept (Reblozyl) plus a Janus kinase inhibitor for ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Sales of Reblozyl were $240 million in the first half of the year, as booked by BMS, with Acceleron claiming a $48 million share of the total.

However, Reblozyl had its indications extended by the FDA last year to include first-line therapy for lower-risk MDS with and without sideroblasts, which BMS said was the key to unlocking $4 ...

Bristol Myers Squibb (BMY) is pushing for Reblozyl’s label expansion despite tough competition and generic pressures.

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Replimune drug rejected by FDA; Omega raises $647M biotech fund The FDA raised issues that Replimune said hadn’t come up in meetings previously. Meanwhile, Omega reloaded with fresh funding to invest ...